GenScript boosts synthetic biology with CustomArray buy

With its acquisition of DNA chip player CustomArray, GenScript is adding new capabilities in CRISPR, protein and antibody engineering to its stable.

Gene synthesis player GenScript is adding new synthetic biology capabilities—in areas such as CRISPR and antibody engineering—with a buyout of CustomArray.

Based in Bothell, Washington, CustomArray offers oligonucleotide pools and DNA microarrays—also called DNA chips or biochips—for applications including DNA libraries and targeted sequencing, as well as CRISPR and protein and antibody engineering. The terms of the deal were not disclosed.

"The acquisition of CustomArray further strengthens our synthetic biology product portfolio with a unique technology that we believe will enhance our customers' ability to accelerate innovation in drug discovery and development, genome editing, protein engineering, and synthetic biology," said GenScript CEO Frank Zhang, Ph.D., in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

CustomArray’s semiconductor chip tech allows it to synthesize DNA directly on the chip surface; it can create thousands of oligonucleotides simultaneously in a high-density and cost-effective way, the company says.

“We are excited to join the GenScript team and excited to capitalize on the opportunity to bring our technology to a much broader range of customers and applications than we could ever reach on our own,” said CustomArray CEO Brooke Anderson. “We look forward to providing products to innovators in the fields of genome editing, biomaterials, agriculture, and more."

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.